CONDENSED CONSOLIDATING FINANCIAL INFORMATION

Core Laboratories N.V. has fully and unconditionally guaranteed all of the Exchangeable Notes issued by Core Laboratories LP in 2006. Core Laboratories LP is an entity 100% indirectly owned by Core Laboratories N.V.

The following condensed consolidating financial information is included so that separate financial statements of Core Laboratories LP are not required to be filed with the U.S. Securities and Exchange Commission (the "SEC"). The condensed consolidating financial statements present investments in both consolidated and unconsolidated affiliates using the equity method of accounting.

The following condensed consolidating financial information presents: balance sheets as of September 30, 2011 and December 31, 2010, statements of operations for each of the three and nine months ended September 30, 2011 and 2010 and the statements of cash flows for each of the nine months ended September 30, 2011 and 2010 of (a) Core Laboratories N.V., parent/guarantor, (b) Core Laboratories LP, issuer of public debt securities guaranteed by Core Laboratories N.V., (c) the non-guarantor subsidiaries, (d) consolidating adjustments necessary to consolidate Core Laboratories N.V. and its subsidiaries and (e) Core Laboratories N.V. on a consolidated basis.



Condensed Consolidating Balance Sheets (Unaudited)
(In thousands)	September 30, 2011
	Core Laboratories N.V. (Parent/ Guarantor)		Core Laboratories LP (Issuer)		Other Subsidiaries (Non- Guarantors)		Consolidating Adjustments			Consolidated Total
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	1,273	$	7,986	$	7,762	$	—		$	17,021
Accounts receivable, net	231		35,914		121,449		—			157,594
Inventories	—		5,461		47,075		—			52,536
Prepaid expenses and other current assets	7,966		5,413		13,893		—			27,272
Total current assets	9,470		54,774		190,179		—			254,423
PROPERTY, PLANT AND EQUIPMENT, net	—		21,014		89,011		—			110,025
GOODWILL AND INTANGIBLES, net	37,318		15,244		117,733		—			170,295
INTERCOMPANY RECEIVABLES	21,868		143,464		681,761		(847,093		)	—
INVESTMENT IN AFFILIATES	599,191		—		1,937,663		(2,535,970		)	884
DEFERRED TAX ASSETS, net	2,167		2,453		1,966		—			6,586
OTHER ASSETS	2,823		11,936		5,929		—			20,688
TOTAL ASSETS	$	672,837	$	248,885	$	3,024,242	$	(3,383,063	)	$	562,901
LIABILITIES AND EQUITY
CURRENT LIABILITIES:
Accounts payable	$	1,014	$	6,849	$	38,913	$	—		$	46,776
Short-term debt and lease obligations	—		84,436		57		—			84,493
Other accrued expenses	2,802		28,820		47,228		—			78,850
Total current liabilities	3,816		120,105		86,198		—			210,119
LONG-TERM DEBT & LEASE OBLIGATIONS	—		—		155,093		—			155,093
DEFERRED COMPENSATION	6,635		15,566		106		—			22,307
DEFERRED TAX LIABILITIES, net	—		—		—		—			—
INTERCOMPANY PAYABLES	518,544		65,908		262,641		(847,093		)	—
OTHER LONG-TERM LIABILITIES	9,460		2,954		24,409		—			36,823
Equity component of short-term debt -senior exchangeable notes	—		509		—		—			509
SHAREHOLDERS' EQUITY	134,382		43,843		2,492,127		(2,535,970		)	134,382
NON-CONTROLLING INTERESTS	—		—		3,668		—			3,668
TOTAL EQUITY	134,382		43,843		2,495,795		(2,535,970		)	138,050
TOTAL LIABILITIES AND EQUITY	$	672,837	$	248,885	$	3,024,242	$	(3,383,063	)	$	562,901



Condensed Consolidating Balance Sheets
(In thousands)	December 31, 2010
	Core Laboratories N.V. (Parent/ Guarantor)		Core Laboratories LP (Issuer)		Other Subsidiaries (Non- Guarantors)		Consolidating Adjustments			Consolidated Total
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	11,162	$	88,612	$	34,106	$	—		$	133,880
Accounts receivable, net	10		33,637		121,079		—			154,726
Inventories	—		4,127		29,852		—			33,979
Prepaid expenses and other current assets	5,641		9,437		11,657		—			26,735
	16,813		135,813		196,694		—			349,320
PROPERTY, PLANT AND EQUIPMENT, net	—		21,139		83,084		—			104,223
GOODWILL AND INTANGIBLES, net	46,986		15,838		100,053		—			162,877
INTERCOMPANY RECEIVABLES	21,749		164,945		242,754		(429,448		)	—
INVESTMENT IN AFFILIATES	553,693		—		1,567,416		(2,120,414		)	695
DEFERRED TAX ASSETS, net	2,810		—		6,436		(9,246		)	—
OTHER ASSETS	3,209		13,099		2,619		—			18,927
TOTAL ASSETS	$	645,260	$	350,834	$	2,199,056	$	(2,559,108	)	$	636,042
LIABILITIES AND EQUITY
CURRENT LIABILITIES:
Accounts payable	$	336	$	5,144	$	39,230	$	—		$	44,710
Short-term debt and lease obligations	—		147,543		—		—			147,543
Other accrued expenses	2,291		29,250		55,559		—			87,100
Total current liabilities	2,627		181,937		94,789		—			279,353
DEFERRED COMPENSATION	6,159		14,981		101		—			21,241
DEFERRED TAX LIABILITIES, net	—		11,444		—		(9,246		)	2,198
INTERCOMPANY PAYABLES	333,651		—		95,797		(429,448		)	—
OTHER LONG-TERM LIABILITIES	13,332		1,099		17,615		—			32,046
Equity component of short-term debt -senior exchangeable notes	—		8,864		—		—			8,864
SHAREHOLDERS' EQUITY	289,491		132,509		1,987,905		(2,120,414		)	289,491
NON-CONTROLLING INTERESTS	—		—		2,849		—			2,849
TOTAL EQUITY	289,491		132,509		1,990,754		(2,120,414		)	292,340
TOTAL LIABILITIES AND EQUITY	$	645,260	$	350,834	$	2,199,056	$	(2,559,108	)	$	636,042



Condensed Consolidating Statements of Operations (Unaudited)
(In thousands)	Three Months Ended September 30, 2011
	Core Laboratories N.V. (Parent/ Guarantor)			Core Laboratories LP (Issuer)		Other Subsidiaries (Non- Guarantors)		Consolidating Adjustments			Consolidated Total
REVENUE
Operating revenue	$	—		$	55,777	$	175,567	$	—		$	231,344
Intercompany revenue	486			6,091		37,676		(44,253		)	—
Earnings (loss) from consolidated affiliates	42,418			—		521,367		(563,785		)	—
Total revenue	42,904			61,868		734,610		(608,038		)	231,344
OPERATING EXPENSES
Operating costs	421			28,501		121,390		—			150,312
General and administrative expenses	1,451			9,706		25		—			11,182
Depreciation and amortization	—			1,550		4,188		—			5,738
Other (income) expense, net	(1,088		)	2,972		32,603		(33,939		)	548
Operating income	42,120			19,139		576,404		(574,099		)	63,564
Loss on exchange of Senior Exchangeable Notes	—			31		—		—			31
Interest expense	—			12,062		—		(8,237		)	3,825
Income (loss) before income tax expense	42,120			7,046		576,404		(565,862		)	59,708
Income tax (benefit) expense	(2,747		)	5,817		11,529		—			14,599
Net income	44,867			1,229		564,875		(565,862		)	45,109
Net income (loss) attributable to non-controlling interest	—			—		242		—			242
Net income (loss) attributable to Core Laboratories	$	44,867		$	1,229	$	564,633	$	(565,862	)	$	44,867



Condensed Consolidating Statements of Operations (Unaudited)
(In thousands)	Nine Months Ended September 30, 2011
	Core Laboratories N.V. (Parent/ Guarantor)			Core Laboratories LP (Issuer)			Other Subsidiaries (Non- Guarantors)			Consolidating Adjustments			Consolidated Total
REVENUE
Operating revenue	$	—		$	156,512		$	507,350		$	—		$	663,862
Intercompany revenue	1,255			17,786			108,570			(127,611		)	—
Earnings (loss) from consolidated affiliates	129,126			—			592,170			(721,296		)	—
Total revenue	130,381			174,298			1,208,090			(848,907		)	663,862
OPERATING EXPENSES
Operating costs	979			80,498			357,858			—			439,335
General and administrative expenses	6,066			24,360			37			—			30,463
Depreciation and amortization	—			4,779			12,595			—			17,374
Other (income) expense, net	(145		)	9,581			88,945			(99,557		)	(1,176		)
Operating income	123,481			55,080			748,655			(749,350		)	177,866
Loss on exchange of Senior Exchangeable Notes	—			870			—			—			870
Interest expense	—			95,071			—			(86,387		)	8,684
Income (loss) before income tax expense	123,481			(40,861		)	748,655			(662,963		)	168,312
Income tax (benefit) expense	(8,127		)	16,808			28,146			—			36,827
Net income	131,608			(57,669		)	720,509			(662,963		)	131,485
Net income (loss) attributable to non-controlling interest	—			—			(123		)	—			(123		)
Net income (loss) attributable to Core Laboratories	$	131,608		$	(57,669	)	$	720,632		$	(662,963	)	$	131,608



Condensed Consolidating Statements of Cash Flows (Unaudited)
(In thousands)	Nine Months Ended September 30, 2011
	Core Laboratories N.V. (Parent/ Guarantor)			Core Laboratories LP (Issuer)			Other Subsidiaries (Non- Guarantors)			Consolidating Adjustments		Consolidated Total
Net cash provided by (used in) operating activities	$	296,803		$	(2,406	)	$	(147,568	)	$	—	$	146,829
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures	—			(4,087		)	(14,116		)	—		(18,203		)
Patents and other intangibles	—			(23		)	(154		)	—		(177		)
Business acquisitions, net of cash acquired	—			—			(21,000		)	—		(21,000		)
Proceeds from sale of assets	—			112			571			—		683
Proceeds from insurance recovery	—			—			884			—		884
Premiums on life insurance	—			(1,661		)	—			—		(1,661		)
Net cash used in investing activities	—			(5,659		)	(33,815		)	—		(39,474		)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of debt	—			(71,467		)	(158,000		)	—		(229,467		)
Proceeds from debt	—			—			313,000			—		313,000
Stock options exercised	295			—			—			—		295
Excess tax benefits from stock-based compensation	2,315			—			—			—		2,315
Debt financing costs	—			(1,094		)	(903		)	—		(1,997		)
Settlement of warrants	(219,451		)	—			—			—		(219,451		)
Non-controlling interests - contributions	—			—			1,193			—		1,193
Non-controlling interests - dividends	—			—			(251		)	—		(251		)
Dividends paid	(34,356		)	—			—			—		(34,356		)
Repurchase of common shares	(55,495		)	—			—			—		(55,495		)
Net cash provided by (used in) financing activities	(306,692		)	(72,561		)	155,039			—		(224,214		)
NET CHANGE IN CASH AND CASH EQUIVALENTS	(9,889		)	(80,626		)	(26,344		)	—		(116,859		)
CASH AND CASH EQUIVALENTS, beginning of period	11,162			88,612			34,106			—		133,880
CASH AND CASH EQUIVALENTS, end of period	$	1,273		$	7,986		$	7,762		$	—	$	17,021



Condensed Consolidating Statements of Operations (Unaudited)
(In thousands)	Three Months Ended September 30, 2010
	Core Laboratories N.V. (Parent/ Guarantor)		Core Laboratories LP (Issuer)			Other Subsidiaries (Non- Guarantors)		Consolidating Adjustments			Consolidated Total
REVENUE
Operating revenue	$	—	$	48,856		$	150,365	$	—		$	199,221
Intercompany revenue	356		6,230			37,948		(44,534		)	—
Earnings from consolidated affiliates	42,764		—			69,553		(112,317		)	—
Total revenue	43,120		55,086			257,866		(156,851		)	199,221
OPERATING EXPENSES
Operating costs	346		24,928			100,498		—			125,772
General and administrative expenses	1,416		6,997			3		—			8,416
Depreciation and amortization	—		1,610			4,204		—			5,814
Other (income) expense, net	1,178		3,850			26,265		(32,291		)	(998		)
Operating income	40,180		17,701			126,896		(124,560		)	60,217
Loss on exchange of Senior Exchangeable Notes	—		675			—		—			675
Interest expense	—		24,008			3		(19,996		)	4,015
Income before income tax expense	40,180		(6,982		)	126,893		(104,564		)	55,527
Income tax (benefit) expense	1,626		10,463			4,675		—			16,764
Net income	38,554		(17,445		)	122,218		(104,564		)	38,763
Net income attributable to non-controlling interests	—		—			209		—			209
Net income attributable to Core Laboratories	$	38,554	$	(17,445	)	$	122,009	$	(104,564	)	$	38,554



Condensed Consolidating Statements of Operations (Unaudited)
(In thousands)	Nine Months Ended September 30, 2010
	Core Laboratories N.V. (Parent/ Guarantor)		Core Laboratories LP (Issuer)			Other Subsidiaries (Non- Guarantors)		Consolidating Adjustments			Consolidated Total
REVENUE
Operating revenue	$	—	$	142,403		$	444,057	$	—		$	586,460
Intercompany revenue	1,023		18,436			108,908		(128,367		)	—
Earnings from consolidated affiliates	115,662		—			286,057		(401,719		)	—
Total revenue	116,685		160,839			839,022		(530,086		)	586,460
OPERATING EXPENSES
Operating costs	1,058		75,149			304,070		—			380,277
General and administrative expenses	5,730		18,267			10		—			24,007
Depreciation and amortization	—		4,722			12,612		—			17,334
Other (income) expense, net	2,035		8,852			84,457		(95,852		)	(508		)
Operating income	107,862		53,849			437,873		(434,234		)	165,350
Loss on exchange of Senior Exchangeable Notes	—		675			—		—			675
Interest expense	—		32,175			9		(19,996		)	12,188
Income before income tax expense	107,862		20,999			437,864		(414,238		)	152,487
Income tax (benefit) expense	2,887		21,937			22,252		—			47,076
Net income	104,975		(938		)	415,612		(414,238		)	105,411
Net income attributable to non-controlling interests	—		—			436		—			436
Net income attributable to Core Laboratories	$	104,975	$	(938	)	$	415,176	$	(414,238	)	$	104,975



Condensed Consolidating Statements of Cash Flows (Unaudited)
(In thousands)	Nine Months Ended September 30, 2010
	Core Laboratories N.V. (Parent/ Guarantor)			Core Laboratories LP (Issuer)			Other Subsidiaries (Non- Guarantors)			Consolidating Adjustments		Consolidated Total
Net cash provided by operating activities	$	63,267		$	87,595		$	18,267		$	—	$	169,129
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures	—			(2,899		)	(16,762		)	—		(19,661		)
Patents and other intangibles	—			(3		)	(177		)	—		(180		)
Business acquisitions, net of cash acquired	—			(9,000		)	—			—		(9,000		)
Proceeds from sale of assets	—			11			395			—		406
Premiums on life insurance	—			(1,357		)	—			—		(1,357		)
Net cash used in investing activities	—			(13,248		)	(16,544		)	—		(29,792		)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of debt	—			(24,366		)	—			—		(24,366		)
Stock options exercised	336			—			—			—		336
Excess tax benefit from stock-based payments	798			—			—			—		798
Non-controlling interests - contributions	—			—			156			—		156
Non-controlling interests - dividends	—			—			(181		)	—		(181		)
Dividends paid	(37,095		)	—			—			—		(37,095		)
Repurchase of common shares	(92,077		)	—			—			—		(92,077		)
Net cash used in financing activities	(128,038		)	(24,366		)	(25		)	—		(152,429		)
NET CHANGE IN CASH AND CASH EQUIVALENTS	(64,771		)	49,981			1,698			—		(13,092		)
CASH AND CASH EQUIVALENTS, beginning of period	73,998			95,048			11,999			—		181,045
CASH AND CASH EQUIVALENTS, end of period	$	9,227		$	145,029		$	13,697		$	—	$	167,953